MagForce Nanotechnologies expands management team
To support 2011 product launch and further developments
The Berlin-based company said these new roles will support the launch of its EU-approved therapy for the treatment of brain tumours and the further development of its Nano-Cancer therapy in additional cancer indications.
Christoph Rehfuess joins MagForce as director of intellectual property. He is a European patent attorney with 12years of experience in the biotech intellectual property field at Medigene. He takes responsibility for patents, trademarks, and technical contracts.
Dirk Kautz takes the role of director of business/corporate development. Prior to joining MagForce, he worked for more than 13 years in the medical devices industry, holding management positions in marketing and corporate development at, among others, Nihon Kohden and Biotronik.
Kajo Wiest joins as director of finance and controlling and brings with him more than 10 years of finance and controlling experience at Jerini.
Stacy Wiedenmann becomes director of investor relations and corporate communications and brings with her over 10 years of experience. She has also worked at Jerini.
The fifth new recruit is Hans Joachim Hutt, who will support the company in the area of medical affairs. The firm said his medical training and more than 20 years of experience at pharmaceutical companies, including Boehringer Ingelheim, Sanofi, Bristol-Myers Squibb, and Sanofi Pasteur MSD, will help MagForce establish commercial networks and expand its therapeutic applications.
‘Filling these key company positions is an important step in the transformation of the company from a research and development only business into a commercial company. Additional hiring for the sales and marketing team will be completed by the end of the year,’ said Peter Heinrich, ceo of MagForce.
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Pharmaceutical
MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients
The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
Manufacturing
Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing
New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing
Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility
The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market